The modular protein Alix is a central node in endosomal-lysosomal trafficking and the budding of human immunodeficiency virus (HIV)-1. The Gag p6 protein of HIV-1 contains a LYPx n LxxL motif that is required for Alix-mediated budding and binds a region of Alix spanning residues 360-702. The structure of this fragment of Alix has the shape of the letter 'V' and is termed the V domain. The V domain has a topologically complex arrangement of 11 a-helices, with connecting loops that cross three times between the two arms of the V. The conserved residue Phe676 is at the center of a large hydrophobic pocket and is crucial for binding to a peptide model of HIV-1 p6. Overexpression of the V domain inhibits HIV-1 release from cells. This inhibition of release is reversed by mutations that block binding of the Alix V domain to p6.
The budding and release of nascent virus particles from the infected host cell is an essential phase of the retroviral replication cycle. The budding process requires the trafficking of the Gag polyprotein precursor from its site of synthesis in the cytosol to the appropriate cellular membrane at which virus assembly occurs. Concomitant with particle release from the host cell, the viral protease (PR) cleaves the Gag precursor to generate the mature Gag proteins matrix (MA), capsid (CA) and nucleocapsid (NC). In HIV-1 and equine infectious anemia virus (EIAV), additional domains known as p6 and p9, respectively, are located at the C terminus of the Gag precursor 1 . p6 and p9, and functionally analogous Gag proteins of other retroviruses, encode the so-called 'late' domains that promote the release of virions from the infected cell [2] [3] [4] . Late domains function by co-opting the host cell's endosomal sorting machinery through direct interactions with defined components of the cellular protein trafficking machinery [2] [3] [4] . Three retroviral late domains have been characterized, containing the short sequence motifs P(T/S)AP, PPPY and LYPx n LxxL (where x is any residue and x n is any sequence of n ¼ 1-3 residues), respectively. P(T/S)AP, located in p6, promotes release by interacting with Tsg101, a component of the cellular ESCRT-I protein complex [5] [6] [7] [8] [9] [10] . The PPPY motif, found in the Gag proteins of a number of retroviruses, including murine leukemia virus (MLV) 11 , functions by interacting with Nedd4-like ubiquitin ligases [12] [13] [14] . The human protein Alix was first discovered because of its association with the calcium-binding protein ALG2 (refs. 15,16) and was therefore named ALG2-interacting protein-1 (AIP1) or Alix; here we use the term 'Alix' to differentiate it from other unrelated proteins named 'AIP1' (the HUGO designation for Alix is PDCD6IP). EIAV and HIV-1 contain LYPx n LxxL motifs that promote release through a direct interaction with Alix 9, [17] [18] [19] .
Alix is at a nexus between the endosomal-lysosomal trafficking and cell-death pathways and the cytoskeleton [20] [21] [22] . Alix can function in multiple pathways because of its modular structure. Its first 359 amino acid residues comprise a Bro1 domain, so named for the Bro1 protein, which is the yeast ortholog of Alix. Bro1 domains are conserved boomerang-shaped structures that are targeted to endosomal membranes through binding to the protein CHMP4, known in yeast as Snf 7 (ref. 23) . Residues 360-716 of Alix comprise a second folded domain that is responsible for binding to viral LYPx n LxxL motifs 17, 24 ; however, the function of this region of Alix in normal physiology is still unclear. The C-terminal residues 717-868 comprise a proline-rich domain (PRD), which is predicted to be unstructured. This last region interacts with a wide array of proteins, many of which contain SH3 and other domains that bind proline-rich peptide sequences.
Much of the interest in Alix has focused on its role in endosomal membrane trafficking. The yeast homolog of Alix, Bro1, was discovered as the product of the BRO1 gene (also called VPS31), whose disruption led to a class E vacuolar protein sorting (VPS) defect. Class E VPS defects have a characteristic enlarged cargo-rich compartment adjacent to the vacuole 25 , which is the yeast counterpart of the human lysosome. In addition to BRO1, yeast class E VPS genes encode the subunits of at least four hetero-oligomeric protein complexes: the Vps27-Hse1 complex and ESCRT-I, ESCRT-II and ESCRT-III 25, 26 . The major normal function of the ESCRT network is to sort transmembrane proteins into multivesicular bodies en route to the lysosome [27] [28] [29] . The ESCRT network is hijacked by certain viruses, such as HIV, that use this system to bud from cells by a process topologically equivalent to multivesicular body formation. Alix is a central node in the ESCRT network. The PRD of Alix directly interacts with the Tsg101 (mammalian homolog of yeast Vps23) subunit of ESCRT-I 18, 19 . The ESCRT-III subunit CHMP4 binds the Alix Bro1 domain. Alix associates with endocytic proteins outside of the ESCRT network; for example, its PRD binds the endocytic proteins SETA 30 and endophilin 31 . Alix also binds lysobisphosphatidic acid (LBPA), which may contribute to its targeting to inward-budding vesicles in the late endosome 32 .
The central domain (residues 360-716) is the least-studied region of Alix. Its best defined function is to bind viral LYPx n LxxL motifs 17, 24 . The characterization of this domain is of great interest, given that its overexpression strongly inhibits HIV-1 budding in cell culture 24 . To better understand Alix and the mechanism of its interaction with viral LYPx n LxxL motifs, we have determined the crystal structure of a C-terminally truncated variant of this domain from human Alix, Alix 360-702 . The structure forms the shape of the letter 'V' . We go on to pinpoint the late domain-binding site on one arm of the V and to define its role in viral budding.
RESULTS

Structure of the Alix V domain
The crystal structure of the Alix V domain was determined by MAD from selenomethionyl protein and refined at 2.9-Å resolution ( Fig. 1a and Supplementary Fig. 1 online) . The structure is almost completely a-helical and contains two arms of unequal length arranged at B401 to each other in a V shape. The shorter of the two arms is 75 Å long, contains the N terminus and comprises six a-helices (a1, a2 and a7-a10) and 150 residues. The long arm is 100 Å long and contains the C terminus, five a-helices (a3-a6 and a11) and 194 residues. The topological arrangement of helices in the two arms is complex. The polypeptide chain crosses between the arms three times: between a2 and a3, a6 and a7, and a10 and a11. The overall architecture of each arm is centered around three long helices. The long arm is built around a three-stranded coiled coil comprising a4, a5 and a11.
Helices a7 and a10 of the short arm have some supercoiling, reflecting coiled-coil character, but the other long helix with which they are partnered, a1, is straight. The region of contact between the two arms is modest. Much of the interaction is formed between the C-terminal three turns of a1 from the short arm, and three turns of long-arm helix a11 near its N terminus. Each arm buries an average of 760 Å 2 of solvent-accessible surface area in the overall structure.
The most dramatic surface feature of the structure is a deep and extensive hydrophobic pocket on the long arm (Fig. 1b) . The hydrophobic surface in these pockets stabilizes one of the major symmetry contacts in the crystal lattice. The C terminus of helix a4 and the a4-a5 loop of a lattice-related molecule protrude deep into the gap between the two arms of the V to contact this site. Major lattice contacts are sometimes formed by 'frustrated' interaction sites when crystals are grown in the absence of the normal interaction partner. As such, these contacts can sometimes be useful guides to the identification of functional interaction sites. The exposed side chains of Phe472 and Trp476 of the lattice-related molecule make extensive contacts with the pocket (Fig. 1c) . Both the guanidine and aliphatic portions of the side chain of Arg475 of the lattice-related molecule interact with the pocket as well. The pocket faces into the gap between the arms of the V. The side chain of Leu440 of a4 is at the very bottom of the pocket. The surrounding walls are formed by Phe495, Val498, Ala505, Asp506, Val509 and Cys512 of a5, and Leu666, Asn669, Leu670, Phe676, Tyr677, Leu680, Ile683 and Phe687 of a11 (Fig. 1d) . The side chains of Asp506 and Tyr677 form a hydrogen bond near the bottom of the pocket, one of very few polar features in the pocket. Val498, Phe676 and Tyr677 form a ridge that divides the pocket. Many of these residues are conserved in Alix orthologs (Fig. 2) .
The LYPx n LxxL motif-binding site To test whether the Phe676 pocket is important for LYPx n LxxL motif binding and function, Phe676 and several adjoining residues within the pocket were mutagenized and tested for their ability to bind a p6-derived peptide in vitro. We established that the 16-residue synthetic peptide p6-16 (DKELYPLTSLRSLFGN), which encompasses the LYPx n LxxL motif, binds the Alix V domain with K d ¼ 5-6 mM. This is nearly identical to the 8 mM affinity measured for full-length HIV-1 p6 (ref. 24) , validating the in vitro model system as a means for quantifying the interaction. The most prominent exposed hydrophobic residue, Phe676, was mutated to aspartate to determine whether this residue is involved in essential hydrophobic interactions with HIV-1 p6. The aspartate substitution was selected because the insertion of a charged residue into a hydrophobic interface is highly destabilizing. The mutant F676D is expressed at normal levels but shows no binding to the p6-16 peptide, as measured by isothermal titration calorimetry (ITC), at concentrations of up to 100 mM ( Fig. 3 and Table 1 ).
Having confirmed a role for the Phe676 pocket in LYPx n LxxL motif binding, we explored the surrounding surface using less drastic perturbations. A spectrum of effects was observed. The V509A mutant showed no detectable binding in the ITC assay. Val509 is 12 Å from Phe676, on the opposite side of the groove between helices a5 and a11, and near the crotch of the V. Val498 is 5 Å from Phe676, directly across the a5 and a11 groove, and V498A reduces binding by five-to six-fold. Ile683 is 7 Å from Phe676 and further from the crotch of the V; its mutation I683A has no effect on binding. Cys512 is located at the end of the hydrophobic pocket closest to the crotch of the V and is highly solvent exposed. C512A has marginally higher affinity than that of wild-type Alix. All of these alanine mutant proteins had essentially normal stability, as indicated by their equal levels of expression as recombinant proteins. The mutations collectively span most of the hydrophobic pocket and provide strong confirmation of a direct role of the pocket in LYPx n LxxL motif binding.
Function of the Phe676 site in HIV-1 budding
We have previously demonstrated that overexpression of the V domain of Alix results in inhibition of HIV-1 release. This inhibition is abrogated by mutations in p6 (for example, L41A and L41R) that block the p6-Alix interaction 24 . To validate the importance of Alix Phe676 in p6 binding in vivo, we measured the ability of the F676D mutant Alix V domain to disrupt HIV-1 particle release. HeLa cells were cotransfected with the full-length infectious pNL4-3 molecular clone and control plasmid or were cotransfected with pNL4-3 and vectors expressing wild-type or mutant Alix V domains. The efficiency of virus release was determined by radioimmunoprecipitation analyses (Fig. 4a) , and levels of Alix V domain expression were determined by immunoblotting (Fig. 4b) . As previously observed 24 , overexpression of the wild-type V domain significantly (P o 2 Â 10 À5 ) inhibited particle release. In contrast, the F676D mutation completely abrogated the ability of the V domain to disrupt budding (Fig. 4a,c) . The loss of inhibition was not due to lower expression of the F676D mutant Alix V domain relative to wild-type Alix (Fig. 4b) . The V509A mutant, which had reduced binding activity, inhibited particle release to a lesser extent than wild-type Alix. Notably, the C512A mutant, which had slightly enhanced binding in vitro, had significantly (P o 1.5 Â 10 À4 ) greater ability to inhibit HIV-1 budding (Fig. 4a,c) , relative to the wild-type V domain.
To corroborate the biochemical virus release data, we performed thin-section transmission EM with cells expressing wild-type or mutant Alix V domains. Consistent with the radioimmunoprecipitation data, the wild-type V domain and the C512A mutant potently inhibited budding, as shown by the accumulation of tethered, immature particles at the plasma membrane and the presence of numerous chains of tethered virions and multibudded particles (Fig. 5) . We also observed that Alix V domain expression induced the release of nonspherical particles with irregular electron density in the Gag shell; this phenotype was particularly striking for the C512A mutant. Cultures expressing the V509A mutant V domain showed a mix of normal and tethered particles. Notably, the F676D mutation, which blocked Alix-p6 peptide binding in vitro and abrogated the ability of the Alix V domain to disrupt virus particle production, had no effect on virion release or morphogenesis (Fig. 5) . These results confirm the importance of Alix Phe676 for p6 binding in vivo. 
DISCUSSION
Here we have determined the overall fold of the central domain of Alix, from the end of the Bro1 domain to the start of the presumably unstructured proline-rich domain. This region of Alix has a notably intricate topology. Combining this structure with that of the Bro1 domain from the yeast Alix ortholog Bro1 (ref. 23 ) gives a structural picture of essentially all of the ordered portion of Alix. The major goal of this project was to determine how viral LYPx n LxxL motifs bind Alix. Although we have been unable thus far to obtain a structure of an Alix-LYPx n LxxL motif peptide complex, we have been able to infer the location of the LYPx n LxxL motif-binding site on Alix. The Phe676 pocket is the largest contiguous region of exposed hydrophobic surface area on the structure. Another exposed hydrophobic region on a lattice-related molecule interacts with the Phe676 site, highlighting its potential for interactions. Phe676 and surrounding residues are highly conserved. We were able to confirm the functional requirement for this site by mutating Phe676 and surrounding residues. F676D abrogates binding in vitro to the p6-16 peptide model of the LYPx n LxxL motif. Whereas overexpression of the wild-type Alix V domain inhibits viral budding and release and leads to the production of virions with a defective morphology, the F676D mutation completely reverses these phenotypes. Together with observations that mutations of other residues surrounding Phe676 modulate function both positively and negatively, this establishes with high confidence the location of the LYPx n LxxL motif-binding site on Alix. Other mutations tested corroborate these findings. It is especially satisfying that one of the mutations, C512A, increases both binding affinity and the potency of budding inhibition. It is unclear whether the modest enhancement of binding alone is responsible for increasing the effectiveness of the V domain as an HIV-1 release inhibitor. Cysteine is subject to a wide range of post-translational modifications, including palmitoylation, S-glutathionylation, S-nitrosylation and oxidation to sulfenic acid. Palmitoylation seems unlikely in this context, but the possibility of other cysteine modifications of Alix may warrant investigation. Cys512 is solvent exposed and could be a candidate for a post-translational modification that could interfere with binding. It is noteworthy that the effect of the Alix fragment on virion morphogenesis differs from that typically observed with late-domain mutations. Not only is a marked increase in the number of particles tethered to the plasma membrane observed 24 (Fig. 5) , but also many of the virions released in the presence of the Alix V domain fragment are nonspherical and have an irregular pattern of electron density in their Gag shells. This phenotype is particularly striking with the Alix C512A mutant (Fig. 5) , which has higher affinity for Gag than that of wild-type Alix. We speculate that binding of the Alix fragment to p6 inhibits proper particle assembly in addition to disrupting virion budding. This hypothesis is consistent with our recent observation 24 that the effect of the Alix V domain fragment on Gag processing and particle release is stronger than, and distinct from, the defect induced by mutation of the Alix-binding site in p6.
The secondary structure of HIV-1 p6 has been analyzed in solution by NMR 33 . HIV-1 p6 is largely unstructured but contains two helical regions, one (a1) from residues 14-18, and the other (a2) from residues 33-43. The structural studies were carried out in part in an aqueous trifluoroethanol solution, which enhances a-helix formation and has been postulated to mimic the hydrophobic helix stabilization provided by membranes or hydrophobic protein surfaces. These NMR results are consistent with secondary structure predictions. Helix a2 of p6 corresponds closely to the central ten residues, 35-44, of the LYPx n LxxL motif. In one model for the p6-Alix interaction, p6 a2 might be aligned roughly coaxially with the Alix V domain long arm. The hydrophobic pocket is B30 Å long, which is more than sufficient to accommodate a three-turn, 10-residue helix. In this model, helix a2 of p6 would form a small four-helix bundle together with Alix a4, a5 and a11. An example of such a recognition mechanism is provided by the helical LD motifs of paxillin, which bind coaxially to the fourhelix-bundle FAT domain 34, 35 . Portions of the LYPx n LxxL motif-binding site are conserved in organisms as diverse as yeast (Fig. 2) , whereas other portions of the site are not well conserved. Phe676 and adjacent residues on a11 are among the most highly conserved in the Alix family, suggesting a conserved physiological function. In contrast, residues on a5 are less well conserved. Val498, which we found has a role in LYPx n LxxL motif binding, is replaced by hydrophilic residues in Dictyostelium discoideum and Arabidopsis thaliana, for example. The partial conservation of the site suggests that it has physiological ligands. Motifs of this form are abundant in proteomes. For example, a search of the yeast proteome where leucine or isoleucine was allowed at the 'L' position, and phenylalanine or tyrosine at the 'F' position, identified 150 occurrences in 143 different yeast proteins. Most of these proteins had no obvious connection to pathways in which Alix is known to participate. The identification of host V domain ligands remains a significant challenge for the field. Other challenges for the Alix field include understanding the physiological significance of its interactions with lipids and with endosomal, cytoskeletal and apoptotic proteins. Together with previous work on the Bro1 domain of the yeast homolog of Alix 23 , these findings on the V domain lay the structural foundation for advancing understanding of Alix and its homologs.
METHODS
Cloning and protein preparation. Human Alix V domain constructs consisting of residues 360-702 and 364-702 were cloned into parallel GST2 vectors 36 , using a standard PCR-based cloning strategy, from complementary DNA encoding Alix. Site-directed single and double mutants were generated using the QuikChange mutagenesis kit (Stratagene). Construction of the mammalian cell expression vector encoding the hemagglutinin epitope (HA)-tagged Alix fragment has been described 24 . All the constructs were verified by DNA sequencing. Alix V domains were overexpressed as N-terminal glutathione S-transferase (GST) fusion proteins in Escherichia coli strain BL21(DE3). Cells were grown at 37 1C, induced with 0.5 mM IPTG at an optical density of 1.0 and further incubated at 20 1C overnight. Harvested cells were resuspended in buffer A (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 7 mM b-mercaptoethanol), lysed and centrifuged. The supernatant was applied to a glutathione-Sepharose column (Amersham) in buffer A and washed with buffer B (50 mM Tris-HCl (pH 7.4), 500 mM NaCl, 7 mM b-mercaptoethanol). His 6 -tagged tobacco etch virus protease was added to cleave the Alix V domains from the GST fusion partner and then removed by passage through TALON resin (BD Bioscience) in buffer A. The cleaved protein was concentrated and applied to a Superdex 200 column (Amersham) in buffer C (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM DTT). Fractions containing Alix V domains were pooled and concentrated using a VivaSpin concentrator (Viva Science). Selenomethionine derivative was expressed in B834(DE3)pLysS (Calbiochem) and purified in the same way as the native protein. All the mutants were purified as described above.
Crystallization, data collection and structure determination. Crystals of Alix 360-702 were grown by the hanging drop method at 22 1C. The reservoir solution contained 0.1 M Tris-HCl (pH 8.5), 13%-15% (w/v) PEG 6,000 and 6%-10% (w/v) ethylene glycol. Crystals appeared overnight and were flashfrozen under liquid nitrogen. Data were collected at 1001 K at beamline X25 of the National Synchrotron Light Source and processed with HKL2000 (HKL Research). A three-wavelength MAD dataset from a selenomethionyl crystal was used for phasing, with the peak, inflection and remote wavelength data sets collected at 0.9795, 0.9799 and 0.9600 Å , respectively. Three selenium sites were located, of five expected in the sequence, using automated Patterson searching 37 . Subsequent solvent flattening by RESOLVE 38 produced an interpretable map. Iterative manual model building and initial refinement were done using O 39 and CNS 40 , respectively. Final refinement was done using REFMAC with TLS parameters incorporated 41 . Statistics for data processing and refinement are listed in Table 2 . All the structural figures were generated using PyMOL 42 .
Isothermal titration calorimetry. The HIV-1 p6-16 peptide has been described 24 . The peptide and the Alix 364-702 protein samples were in 10 mM HEPES (pH 7.4), 150 mM NaCl and 2 mM DTT. The concentrations were 400 mM for the p6-16 peptide and 15-20 mM for the Alix proteins. ITC measurements were done on a MicroCal VP-ITC at 25 1C. The peptide was injected into the Alix 364-702 samples in 29 aliquots of 10 ml each at 240-s intervals. Data obtained from the peptide injections into the buffer blanks were subtracted from the experimental data for analysis using MicroCal Origin software.
Cell culture, metabolic labeling, virus release assays and western blotting. HeLa cells were maintained in DMEM supplemented with 5% (v/v) FBS, L-glutamine (2 mM), penicillin and streptomycin. Transfections were done with Lipofectamine 2000 (Invitrogen) as recommended by the supplier. Methods used for metabolic radiolabeling, preparation of cell and virus lysates, and immunoprecipitation have been described in detail 43, 44 . Briefly, transfected HeLa cells were starved in Cys/Met-free medium for 30 min and then metabolically radiolabeled for 2 h with [ 35 S]Cys/Met Pro-mix (Amersham). Virions were pelleted by ultracentrifugation. Cell and virus lysates were immunoprecipitated with pooled immunoglobulin from HIV-1-infected patients (HIV-Ig; see Acknowledgments). The radioimmunoprecipitated proteins were separated by SDS-PAGE, then visualized by fluorography and quantified by phosphorimaging analysis. Virus release efficiency was calculated as the amount of released virion-associated Gag as a fraction of total Gag (cell plus virion) synthesized during the 2-h labeling period, normalized to the level of Alix fragment expression. Alix V domain expression was monitored by western blotting with an antibody to HA (HA-7, Sigma) and quantified using an Alpha Innotec FluorTec SP chemiluminescence imager. Statistical significance of the virus release data was determined with Student's t-test.
Electron microscopy. Cells were cotransfected with pNL4-3 plus control plasmid or were cotransfected with pNL4-3 and Alix V domain expression vectors. Cells were washed in PBS, fixed in glutaraldehyde for EM analysis as described 45 and examined under a Hitachi H7000 electron microscope. Bond angles (1) 1 . 1 6
One crystal was used to determine the structure. Values in parentheses are for highestresolution shell. a R free is calculated for a randomly chosen 10% of reflections.
